Jump to content

Berwian, 2017 Predicting relapse after antidepressant withdrawal - a systematic review.


Altostrata
 Share

Recommended Posts

  • Administrator

ADMIN NOTE E-mail sent to lead author of paper with cc to journal editor.

 

Dr. Berwian —

 

I read with interest your paper Psychol Med. 2017 Feb; 47(3): 426–437. Predicting relapse after antidepressant withdrawal – a systematic review.

 

I believe the conclusion of your paper is correct, medicine cannot predict who will relapse after discontinuation of antidepressants. However, I must make a very important point: If you look closely at the 13 studies you included in your review, you will see that not a single one includes a protocol for distinguishing relapse from antidepressant withdrawal or discontinuation syndrome.

 

Instead, all of them evaluated post-discontinuation condition on some kind of depression scale. If a patient was feeling poorly from withdrawal symptoms, he or she had no choice but to indicate that somehow in the context of “depression” — even if the symptoms were the very common dizziness, disorientation, "brain zaps", nausea, or sleeplessness, all withdrawal symptoms that are not relapse of depression but might cause anyone to feel down.

 

Failure to identify withdrawal symptoms and the consequent misdiagnosis as relapse has confounded all studies of antidepressant efficacy and relapse after discontinuation. This may be why you found predictive value of these studies to be very weak.

 

Given that physicians, even academic psychiatrists, are so poorly informed about gradual tapering techniques and identifying withdrawal symptoms, it may very well be that the most common outcome of antidepressant discontinuation is not “relapse” but withdrawal syndrome.

 

In fact, true relapse in such situations may be rare, and millions of people have been erroneously continued on chronic antidepressant treatment for years merely to avoid withdrawal symptoms.

 

Please consider this should you follow up on your 2017 publication.

 


 

Psychol Med. 2017 Feb;47(3):426-437. doi: 10.1017/S0033291716002580. Epub 2016 Oct 27.

Predicting relapse after antidepressant withdrawal - a systematic review.

Berwian IM1, Walter H2, Seifritz E1, Huys QJ1.

 

Abstract and free full text at https://www.ncbi.nlm.nih.gov/pubmed/27786144

 

A substantial proportion of the burden of depression arises from its recurrent nature. The risk of relapse after antidepressant medication (ADM) discontinuation is high but not uniform. Predictors of individual relapse risk after antidepressant discontinuation could help to guide treatment and mitigate the long-term course of depression. We conducted a systematic literature search in PubMed to identify relapse predictors using the search terms '(depress* OR MDD*) AND (relapse* OR recurren*) AND (predict* OR risk) AND (discontinu* OR withdraw* OR maintenance OR maintain or continu*) AND (antidepress* OR medication OR drug)' for published studies until November 2014. Studies investigating predictors of relapse in patients aged between 18 and 65 years with a main diagnosis of major depressive disorder (MDD), who remitted from a depressive episode while treated with ADM and were followed up for at least 6 months to assess relapse after part of the sample discontinued their ADM, were included in the review. Although relevant information is present in many studies, only 13 studies based on nine separate samples investigated predictors for relapse after ADM discontinuation. There are multiple promising predictors, including markers of true treatment response and the number of prior episodes. However, the existing evidence is weak and there are no established, validated markers of individual relapse risk after antidepressant cessation. There is little evidence to guide discontinuation decisions in an individualized manner beyond overall recurrence risk. Thus, there is a pressing need to investigate neurobiological markers of individual relapse risk, focusing on treatment discontinuation.

 

 

Table 1 is the list of the studies included in the above review, with their evaluating instruments: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244448/table/tab01/

 

Also see pdf of Table 1 at https://drive.google.com/open?id=13FmKRp4wSlJ4vkbdh2mcqIhXuwxPy0qP

This is not medical advice. Discuss any decisions about your medical care with a knowledgeable medical practitioner.

"It has become appallingly obvious that our technology has surpassed our humanity." -- Albert Einstein

All postings © copyrighted.

Link to comment
Share on other sites

Do any studies of withdrawal include people treated for conditions other than depression or anxiety?  Antidepressants are used for so many physical disorders including premature ejaculation, low blood pressure, etc. It would be interesting to see cases like that included. 

Pristiq tapered over 8 months ending Spring 2011 after 18 years of polydrugging that began w/Zoloft for fatigue/general malaise (not mood). CURRENT: 1mg Klonopin qhs (SSRI bruxism), 75mg trazodone qhs, various hormonesLitigation for 11 years for Work-related injury, settled 2004. Involuntary medical retirement in 2001 (age 39). 2012 - brain MRI showing diffuse, chronic cerebrovascular damage/demyelination possibly vasculitis/cerebritis. Dx w/autoimmune polyendocrine failure.<p>2013 - Dx w/CNS Sjogren's Lupus (FANA antibodies first appeared in 1997 but missed by doc).

Link to comment
Share on other sites

@Altostrata Just bless you for caring so deeply here and for persevering so tenaciously in your efforts to educate prescribers and others.  It is amazing to me.  Hopefully soon those following behind us will reap the benefits of your work and the work of the other staff here and not find themselves in  situations such as ours.  I copy these to take to my doctor.  Thank you for sharing!  

-Nardil 1976 < year, stopped. React to AD's. Klonopin .5BID 1990, 2.5mg til 2016

-Klonopin doubled Jan '16. Taper to 2.25mg May to Nov '16. Bad react to Lexapro, stop. React to Prevacid too, taper off. 

-November '16 Tapered .25mg Klonopin in hospital. Jan '17 started Viibryd, 20mg from Feb to June '17,     

-20mg to 10mg Viibryd from 3/25 to 6/10 2017, 12/15 10% Viibryd taper...back up next day

-Clonazepam 2mg to 1.85mg 4/14 '17 to end November; taper to 1mg Clonazepam in hospital 9/1 tp 9/14 '17

-Feb '18 Amiloride .25mg  5/18 off Amiloride d/t react. Clonaz compounded  

-4/27 '18 Viibryd 9.5mg, 6/11 9.0 mg, 1/27 '19 Viibryd 8.75mg, ; Clonazepam .2mg 530pm and .7mg 1130pm, Premarin .3mg 830PM CARAFATE QID 2/27/19 to 3/5/19

-July 6'19 1/2 10mg Claritin 230pm, stopped it about July 18, started Oct 11 '19, 

-7/27 Viibryd 8.5, 8/29 8.25, 10/24 8.0, 12/19 7.75, Feb '20 7.50, 3/20 7.25, 5/20 7.0, 6/20 6.75, 7/20 6.5, 8/20 6.25, 10/2 20 6.0, 11/25'20 5.75, 1/9/21 5.5, 2/23 5.25

-1015 AM Viibryd, vit D 4,000IU 130, 415 Clonazepam .2mg, 815 Premarin .3mg, 1015 Clonaz .7mg,

  1115 3t fish oil+D 1145 Castor Oil 650mg(4) 1230 Carafate 1/2GM,Methylated B Vit  1/week,Reacted Mag prn

Link to comment
Share on other sites

  • Administrator

Thank you, Rabe.

 

How does your doctor respond?

This is not medical advice. Discuss any decisions about your medical care with a knowledgeable medical practitioner.

"It has become appallingly obvious that our technology has surpassed our humanity." -- Albert Einstein

All postings © copyrighted.

Link to comment
Share on other sites

  • 3 months later...
On 9/11/2018 at 11:58 AM, Altostrata said:

ADMIN NOTE E-mail sent to lead author of paper with cc to journal editor.

 

Dr. Berwian —

 

I read with interest your paper Psychol Med. 2017 Feb; 47(3): 426–437. Predicting relapse after antidepressant withdrawal – a systematic review.

 

I believe the conclusion of your paper is correct, medicine cannot predict who will relapse after discontinuation of antidepressants. However, I must make a very important point: If you look closely at the 13 studies you included in your review, you will see that not a single one includes a protocol for distinguishing relapse from antidepressant withdrawal or discontinuation syndrome.

 

Instead, all of them evaluated post-discontinuation condition on some kind of depression scale. If a patient was feeling poorly from withdrawal symptoms, he or she had no choice but to indicate that somehow in the context of “depression” — even if the symptoms were the very common dizziness, disorientation, "brain zaps", nausea, or sleeplessness, all withdrawal symptoms that are not relapse of depression but might cause anyone to feel down.

 

Failure to identify withdrawal symptoms and the consequent misdiagnosis as relapse has confounded all studies of antidepressant efficacy and relapse after discontinuation. This may be why you found predictive value of these studies to be very weak.

 

Given that physicians, even academic psychiatrists, are so poorly informed about gradual tapering techniques and identifying withdrawal symptoms, it may very well be that the most common outcome of antidepressant discontinuation is not “relapse” but withdrawal syndrome.

 

In fact, true relapse in such situations may be rare, and millions of people have been erroneously continued on chronic antidepressant treatment for years merely to avoid withdrawal symptoms.

 

Please consider this should you follow up on your 2017 publication.

 


 

Psychol Med. 2017 Feb;47(3):426-437. doi: 10.1017/S0033291716002580. Epub 2016 Oct 27.

Predicting relapse after antidepressant withdrawal - a systematic review.

Berwian IM1, Walter H2, Seifritz E1, Huys QJ1.

 

Abstract and free full text at https://www.ncbi.nlm.nih.gov/pubmed/27786144

 

A substantial proportion of the burden of depression arises from its recurrent nature. The risk of relapse after antidepressant medication (ADM) discontinuation is high but not uniform. Predictors of individual relapse risk after antidepressant discontinuation could help to guide treatment and mitigate the long-term course of depression. We conducted a systematic literature search in PubMed to identify relapse predictors using the search terms '(depress* OR MDD*) AND (relapse* OR recurren*) AND (predict* OR risk) AND (discontinu* OR withdraw* OR maintenance OR maintain or continu*) AND (antidepress* OR medication OR drug)' for published studies until November 2014. Studies investigating predictors of relapse in patients aged between 18 and 65 years with a main diagnosis of major depressive disorder (MDD), who remitted from a depressive episode while treated with ADM and were followed up for at least 6 months to assess relapse after part of the sample discontinued their ADM, were included in the review. Although relevant information is present in many studies, only 13 studies based on nine separate samples investigated predictors for relapse after ADM discontinuation. There are multiple promising predictors, including markers of true treatment response and the number of prior episodes. However, the existing evidence is weak and there are no established, validated markers of individual relapse risk after antidepressant cessation. There is little evidence to guide discontinuation decisions in an individualized manner beyond overall recurrence risk. Thus, there is a pressing need to investigate neurobiological markers of individual relapse risk, focusing on treatment discontinuation.

 

 

Table 1 is the list of the studies included in the above review, with their evaluating instruments: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244448/table/tab01/

 

Also see pdf of Table 1 at https://drive.google.com/open?id=13FmKRp4wSlJ4vkbdh2mcqIhXuwxPy0qP

 

Given that physicians, even academic psychiatrists, are so poorly informed about gradual tapering techniques and identifying withdrawal symptoms, it may very well be that the most common outcome of antidepressant discontinuation is not “relapse” but withdrawal syndrome.

 

Thank God I read this. I'm sure now this is the reason I and so many others have been on the AD merry go round for years 

I don't know whether to feel angry 😡 or sad 😔 right now. 

Edited by Altostrata
removed duplicate quote

Lexapro 10MG

Almost continually for 25 odd years 

Reduced to 5MG beginning July 2018-  end August 2018

August 2018 til now off completely 

 

 

 

 

Link to comment
Share on other sites

  • Administrator

Exactly.

This is not medical advice. Discuss any decisions about your medical care with a knowledgeable medical practitioner.

"It has become appallingly obvious that our technology has surpassed our humanity." -- Albert Einstein

All postings © copyrighted.

Link to comment
Share on other sites

 Share

×
×
  • Create New...

Important Information

Terms of Use Privacy Policy